THE PATENTABILITY OF CHEMICAL INTERMEDIATES
The Constitution provides that: "The Congress shall have Power...
To promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to their respective Writings and Discoveries." 1 Congress has exercised this power since 1790 by passing statutes which regulate the issuance of patents. In each of these statutes there has been a requirement that an invention, in order to receive a patent, be useful. 2 Utility has never been defined in the pertinent section of the patent statute. 3 Section 101 of Title 35 of the United States Code, which contains the utility requirement of the present patent statute, is no exception. 4 Section 112 of Title 35 requires that the inventor disclose to those skilled in the art how to use the invention. 5 It is the purpose of this Comment to discuss the utility and disclosure requirements as they relate to chemical compounds useful as intermediates in the formation of other compounds and to the processes which produce such intermediates. Part I presents an historical background of these requirements in the area of chemical patents. Part II analyzes the current law as set out in two recent decisions of the Circuit Court of Customs and Patent Appeals and an earlier Supreme Court decision. Finally, Part III suggests a standard of utility which would alleviate some of the problems in this area. application must assert the invention's utility and indicate its use. The court, relying on the predecessors of sections 101 and 112, said that no process or product compound was patentable if not useful. Prior to this time, lack of utility of a chemical compound had never been grounds for rejecting a chemical patent application.
14 The so-called "Bremner rule," that the patent application must assert utility and indicate the use or uses for both product and process claims, replaced the concept of inherent utility. 5 Assertion of a compound's utility as an intermediate in the formation of another compound was no longer sufficient to satisfy the utility requirement.' 6 In one court's view, a description of the compound's important characteristics, such as insolubility in acids and capability of depositing a particular film, failed to meet the requirements.'
j. In re Nelson-A New Trend or Return to pre-Bremner Law
In 1960 the Circuit Court of Customs and Patent Appeals decided In re Nelson.' 8 The patent application in that case described how claimed compounds produce analogous compounds which belonged to a class of chemicals some of which had a known use. The court held that this was sufficient to satisfy the utility requirements of section 101 and that disclosing the method of converting one compound into another was sufficient to satisfy the requirements of section 112.0 The court specifically repudiated" an earlier decision 2 ' which had held a description of a claimed compound's characteristics insufficient to satisfy the utility requirement.
Nelson represented a return to the interpretation of the utility requirement which prevailed before In re Bremner. The court held that, because the application carried an implicit assertion of utility, explicit assertion was unnecessary to satisfy the requirements of utility and dis- 154, 183 (1964) .
'G See Note, 14 A.m. U.L. REv. 78, 80 (1964 This prediction showed promise of fulfillment in the years immediately following the Nelson decision. In a series of decisions between 1960 and 1965 the Circuit Court of Customs and Patent Appeals reestablished a liberal view of the utility requirement very similar to the one prevailing prior to Bremner. 24 The first of these cases distinguished between chemical compounds and chemical processes as they relate to the requirements of disclosure in section 112 . 25 The court stated that where the claim is for a process, it is unnecessary that the specification teach a use for the compound which is the product of the process, as the decision in Bremner had required. The opposite result, according to the court, would require the applicant to teach a use for something which he had not claimed.
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The court next decided a case involving the difficult question of section 112's impact on compounds useful as intermediates in the formation of other compounds. Focusing on what a chemist would know about such compounds, the court held that the disclosure of their usefulness as intermediates was sufficient to satisfy the requirements of section 112. some members of which have a known use, or they may have no known present use although they are the objects of current scientific investigation. 48 The compounds in Bremner, Nelson, Manson, Kirk and Joly all belonged to a class of compounds known as steroids which possess a nucleus with a unique structural configuration of carbon and hydrogen atoms. 4 4 Steroids include a wide range of naturally occurring compounds such as the sterols proper, bile acids, sex hormones, adrenocortical hormones, cardiac glycosides, sepojenins, and some alkaloids 4 Consequenfly, the decision as to the patentability of these compounds would have great importance for the chemist and biologist even if this were the only class of compounds involved. Patentability assumes greater significance in light of the ability of all organic compounds and of many inorganic compounds to act as intermediates in forming other compounds. Probably the most important question in this inquiry is which interpretation of the utility requirement is more likely to implement congressional intent in establishing utility as a prerequisite for patentability. Many assert that scientific progress is the basic purpose of the patent system, 4 7 while others place greater emphasis on a short term commercial benefit to the general public 4 These two purposes may at times be harmonious and at other times irreconcilable. Because Congress has not defined the utility requirement, one must seek elsewhere for the meaning of the term "useful."
A. Brenner v. Manson
The Supreme Court in Brenner v. Manson reinstated the "rule of Bremner" into the patent law. 49 There are fundamental problems with the Manson decision. First, the Court did not, as it thought, return to well-established doctrine by invoking Bremner's utility requirement.
The Supreme Court saw the decision in Bremner as representing the established law with respect to the utility requirement for chemical patents. The Nelson decision, in the Court's view, was a departure from the established rule. 50 But this interpretation of the utility requirement's history, as Justice Harlan indicates in his dissent, failed to take account of the law prior to Bremner, holding that chemical compounds including those whose only use was as an intermediate in the formation of other compounds, possessed inherent utility. 51 Nelson was actually a return to, rather than a departure from, the prevailing view of the utility requirement. 52
Secrecy and Research
The second problem with the Manson decision is the Court's reasoning with respect to the degree to which its holding would frustrate the disclosure goals of the patent laws. The Court recognized the possibility that inability to patent a process such as the one which Manson claimed in his application might tend to discourage disclosure and lead to greater, 53 This statement, if true, applies equally well to a patent application which contains a claim to a compound or process with a commercial use. The appropriate remedy for such a defect is refusal to grant patents wherever there is insufficient disclosure rather than refusal to grant patents where the claimed invention is useful only in research.
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The Court viewed the tendency toward secrecy where an inventor cannot receive a patent for his compound as exaggerated: If the inventor is unable to find a use for his invention, he will want to disclose it to someone who can find a use for it." However, this does not appear necessarily to be true. It seems at least as likely that the inventor would want to withhold disclosure until he could gain patent protection after finding some use for his invention. This would certainly be the case if he acted in his economic self-interest. 55 The Court stated that disclosure of a patented process will not stimulate research into new uses for it because the patentee can enforce his patent against subsequent researchers.
57 However, section 100 of the patent statute provides that processes, which are patentable under section 101, include new uses of a known process. 5 5 This means that if a second researcher discovers a new use for the known process, he may receive a patent for it. He would then have a legal right to stop the original inventor from using the process in the new manner, whereas the original inventor could legally stop the second researcher from using the process in any manner whatsoever, including the new manner. In this situation there is an incentive for the two inventors to work out some 53 383 U.S. at 533-34. 54 For an excellent discussion of the Supreme Court's arguments in Brenner v. Manson see Velvel, supra note 34. Velvel suggests that because the patent drafting techniques tend to minimize disclosure even where the invention is useful commercially, and considering that such inventions do receive patents, then, by a "parity of reasoning," research inventions should receive patents too. Id. at 6-7.
55 383 U.S. at 534. mutually profitable cross-licensing agreement." The possibility of crosslicensing provides the second researcher with the motivation to experiment with the known process in the first place.
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There is admittedly a possible difficulty with this argument. The original patentee has the right to prevent anyone from even experimenting with his patented process. Generally, he will not do this because it would not be in his economic self-interest." The patentee wants to obtain a patent so that he can place his process into the hands of others with the assurance that he will receive compensation for it. The patentee knows that his patent becomes more valuable to him through the development of new uses of his invention. There is, however, a very important exception to the general rule that a patentee will not attempt to prevent research with his process. If the original patentee is a large corporation with all the necessary research facilities to conduct its own research into the process' uses, it will have no economic incentive to license others to do the research. Even though this exception may be extremely important because of the size and relative independence of many patentees, it is clear that the issuance of patents on such processes will not limit research into their uses. On the one hand, the large chemical corporation does the research itself, while on the other hand, the patentee who does not have the resources to do his own research has an economic incentive to license others to do so. Moreover, the original patentee's right to prevent others from experimenting with his process is, as a practical matter, unenforceable.'
The reason for this is that such experimentation ordinarily occurs on the infringer's own property which is relatively secret from public observation.
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In summary, the Supreme Court in Manson argued that failure to receive patent protection would not produce undesirable secrecy and that, in any event, disclosure of a new process would not necessarily stimulate research into new uses for that process. Hence, not granting a patent for the process would not deter the progress of science. It seems more reasonable, however, that if an inventor cannot receive patent protection for his invention, he will withhold disclosure until he can discover some use for his invention. Undesirable secrecy could result. 6 8 It is also reasonable that disclosure will stimulate research into new uses for the invention, thus promoting the progress of science. 66
The Monopoly of the Patent Grant
Finally, the Manson decision emphasized the public's economic benefit to be derived from a patent monopoly, to the exclusion of the derivative benefits it would receive from increased chemical research. The Court believed that granting a patent for a process whose end product compound is useful only as an intermediate would lead to a monopoly over a potentially vast area. Such a patent might block off whole fields of research, the Court argued, without a compensating benefit to the public.
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The Supreme Court said that the quid pro quo for granting the patent monopoly is the benefit to society. When there is no "specific benefit.., in currently available form," 6 8 there is nothing to compensate the public for the price it pays in allowing the patentee a monopoly on his invention. In this view, there is apparently insufficient benefit to the public deriving from a discovery which facilitates research to justify the granting of the patent monopoly. By emphasizing commercial benefit currently available to the public, the Court did not mention any benefit which might be incidental to an increased rate of chemical research. 0
B. Kirk and Joly
In addition to the problems with the Manson decision itself, there are difficulties in applying it to the patent applications for steroid intermediates of Kirk and Joly. Manson contains language which indicates that products and processes are to receive similar treatment with respect to the utility requirement and that neither is patentable if useful only in research 0 The Circuit Court of Customs and Patent Appeals decided in Kirk and Joly that compounds useful only as intermediates in the production of other compounds which have no present known use other than as objects of scientific investigation did not satisfy the utility requirement of section 101, and the disclosure of how to use these compounds as intermediates did not satisfy the requirements of section 112.71 
Interference Proceedings
The purpose of an interference proceeding, brought before the Patent Office, 4 is to determine which of two or more parties claiming the same invention is the prior inventor.Th The Kirk and Joly dissenters contended that the issue of utility is not the same issue in an ex parte proceeding as it is in an interference proceeding because the utility requirement is much stricter in the latter context, and therefore a decision that an invention lacks utility in an interference proceeding as in Manson is not binding on the issue of utility in an ex parte proceeding as in Kirk and Joly 7
The main difference between those who think that the issue of utility in an interference and in an ex parte proceeding is the same and those who think there is a fundamental difference lies in their differing views as to the nature of the interference proceeding. Those finding similarity see the interference proceeding as composed of two parts. The first part is the determination of patentability of the invention with respect to both parties. Only when the Patent Office has found the invention patentable will it consider the question of priority. 77 ference see the interference proceeding as a single unit in which the question of priority of invention is the crucial issue which receives first consideration. To establish priority of invention, the inventor must prove an actual reduction to practice, which is a more stringent requirement than the requirement of utility in an ex parte proceeding. Therefore, they conclude, a refusal to grant an interference because the inventor has not established priority should not be binding on the issue of the invention's utility in an ex parte proceeding. 7 8 Each application in an interference proceeding must be such that it could result in a valid patent in an ex parte proceeding." Such a determination requires the Patent Office to measure the sufficiency of the application and the patentability of the invention by the same statutory standards as in an ex parte proceeding, including the standard of utility in section 101 and the standard of disclosure in section 112. 80 This supports the conclusion that the decision on the patentability of research compounds and processes does not depend on the procedural context, whether interference or ex parte, in which the issue arises. The decision in Brenner v. Manson that the claimed process was not patentable would accordingly be binding on the issue of the process's patentability even though it arose in an ex parte proceeding.
Process v. Product
Some have urged that there should be different standards of utility depending on whether the claimed invention is a compound or a process. 8 ' Most of these arguments contend that the requirement of utility for a process should be nothing more than that the process perform the function which the inventor intended it to fulfill; the court should not look "The following prerequisites are essential to the institution of an interference between two or more applications:
(a) Each application must have been filed in such complete form as to have entitled the applicant to an examination of his application on the merits. to the utility or nonutility of the product compound in order to determine whether or not the process is useful because to do so would require the inventor to teach the manner of using a product which he did not claim and which was not his invention. Therefore, the argument concludes, a decision that a process does not possess utility cannot be controlling on the issue whether the process's product compounds possess utility." This was one of the bases on which the dissenters in Kirk and Joly distinguished those cases from Manson.
3
Which of these viewpoints one holds depends largely on his interpretation of the policies underlying the granting of the patent monopoly. If one believes, as the Supreme Court did in Brenner v. Manson, that the emphasis should be on some "specific benefit . . . in currently available form, 8 4 then he will quite reasonably look to the utility of the product compounds in determining the utility of the process. If one believes, on the other hand, that the benefits from progress in research are sufficient to justify the granting of the patent monopoly, then he will reasonably consider the functioning of the process as sufficient to satisfy the utility requirement without regard for the utility of the product compound.
The Relationship Between Sections 101 and 112
Those who believe that compounds which are useful in research either directly or as intermediates possess patentable utility maintain that research itself is a useful field of human endeavor. One difference between this view and the view that such compounds lack patentable utility lies in whether one interprets sections 101 and 112 separately or together. The majority in Kirk and Joly argued that the two sections should be read together and that the disclosure requirements of section 112 presuppose full compliance with the requirements of section 101. The court said that any other interpretation of the requirements would anomalously require an applicant "to teach how to use a useless invention." 8 6 If one reads section 101 as requiring some specific benefit to the general public, he will necessarily read sections 101 and 112 together. Otherwise, there would be no requirement that the inventor disclose the benefit to the public because section 101 requires no disclosure. But reading the sec- tions separately appears more reasonable because section 112 makes specific reference to the knowledge of those skilled in the art, whereas section 101 does not. In any event, if the sections are read together, it would appear more reasonable to interpret section 101's utility requirement by the standard of knowledge of one skilled in the art than to interpret section 112 to require disclosure of some specific benefit in apparent disregard of that section's language.
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III CRITIQUE AND SUGGESTION FOR A STANDARD OF UTILITY
The Supreme Court in Brenner v. Manson considered the quid pro quo for the granting of the patent monopoly to be the benefit to the public. 8 8 Unless the invention provided some "specific benefit . . . in currently available form," it did not compensate the public for the price it pays in allowing the patentee a monopoly on his invention.
The American economic system attempts to maintain free competition to ensure the greatest possible production and widest possible distribution of goods and services to the public. The ideal of a competitive economy is opposed to an economy dominated by monopolies which would restrict the total output of society and enlarge the monopolist's share 8 9
The one outstanding exception to the general aversion to monopolies is the patent system.° This exception was predicated on the belief that new inventions would tend to augment the total amount of goods and services available to the public, and should consequently receive encouragement, even at the expense of forfeiting the ideal of free competition for a limited time. Congress received power from the Constitution to provide "patent grants of monopoly for limited periods of time in order to encourage inventive activity."" There are two criticisms of the Supreme Court's emphasis on commercial benefit to the general public as a prerequisite to patentability. First, chemical research is vital to the development of useful products which the public enjoys. The progress of scientific research in this century has been responsible for a direct and significant increase in the produc- 1l BENN=rr, supra note 62, at 80.
[Vol. 56:497 tion and distribution of goods and services. 2 An invention which facilitates research is therefore of direct benefit to the public in that it increases the rate of the progress of science. As an illustration, if a compound is useful as an intermediate in the production of other compounds which are the objects of current scientific investigation, it performs a function which benefits the public. The public has a direct interest in discovering whether those compounds which are the objects of scientific investigation have some therapeutic or other value. In facilitating research into the uses of those compounds, the intermediate is serving that public interest. Such a benefit should be a proper quid pro quo for granting the patent monopoly.
9 3
The second difficulty with the Supreme Court's argument is its apparent implication, unsupported by precedent, that marketability is a prerequisite of patentability. There has never been a requirement that the invention possess greater practicality than another process or composition of matter which can accomplish the same result. 9 " The general rule has been that an invention may be patentable even though commercially impractical. 5 Clearly, the benefit which the public derives from such an invention is minimal because it does not function practically in the commercial world. But it is equally clear that the public has given up nothing valuable by granting a patent monopoly on a commercially worthless invention. 9 6 Other inventions may possess only minimal utility at the time of the granting of the patent and later become extremely valuable to the public and to the patentee through the later development of new and unpredictable uses. For example, it was several years after the granting of a patent for ether that its properties as an anesthetic become apparent9r The same is true of compounds and processes useful in research. They may possess usefulness only as intermediates at the time of discovery. Subsequently they may become extremely valuable through discovery and development of new uses. It is difficult, if not impossible, in many instances, to predict the ultimate value of an invention to the general public. The patentability of the invention has never depended on the predicted degree of future value it may have in the marketplace. There is no apparent reason why the rule should be different in the case of compounds useful as intermediates.
No monopoly, of course, is absolute. Every monopoly is limited by the demand schedule for the product, the pressure of substitutes, the potential competition, the possibility of alienating future demand, and the possibility of intervention by the government, whether or not it is a patent monopoly. Patent monopolies, however, possess further limitations, the primary of which is the possibility of obtaining patents for substitute products or processes. 98 Only a very few of the many patents which issue from the Patent Office cover basic inventions. In the case of most other patents, whether for processes or compositions of matter, the same results are achievable by some alternative process or composition. This possibility, as well as the great difficulty in proving infringement in most cases, decreases the value of the patent monopoly to the patentee as well as the danger that it will cover a potentially vast area without the compensating benefit to the public. ' Eliminating any requirement that a patentable process or product possess a specific degree of utility' 0 0 appears reasonable to the extent that it increases the possibility of choice among products or processes of varying degrees of performance. The patent law carries a presumption that the public receives its compensation for the granting of the patent monopoly when the invention has met the statutory requirements, 0 1 and whether the invention meets those requirements, including the requirement of utility, has never depended on the degree of benefit which the public receives. Insofar as the decisions in Manson, Kirk, and Joly tend to establish a requirement that an invention possess a specific degree of utility before the patent may issue, they intrude into an area where such standards are neither applicable nor desirable. 2 Petitioner argued in Manson that the product compounds of his process might inhibit tumors in mice. Even though such a capability does not appear to satisfy the Court's test that a patentable invention must possess some "specific benefit . . .in currently available form," the Court specifically declined to express an opinion as to the patentable utility of compounds which could produce such an effect.' This indicates that the Court's test may not be rigidly applied. Assuming the question 98 For an excellent discussion of the various factors which limit the monopoly created by the granting of a patent see B=,Trr, supra note 62, at 121-41. is open, it seems that such a process should be patentable because the resulting wide-spread dissemination of information about the process has a great social value. Disclosure of and experimentation with the process is highly desirable before it has developed to the stage where it can actually inhibit tumors but after the discoverer can say with some assurance that it will be useful in a particular field of research. Because society benefits from scientific research generally, and disclosure of new processes will stimulate research, there is a benefit to society in disseminating information about the process. Providing chemists with the information quickly enhances the possibility that they will be able to solve their research problem at a faster rate than if each must discover the process independently.°4 Such an increase in the possibilities of developing the process is worth the price of granting the patent monopoly. The decisions in Manson, Kirk and Joly seem effectively to exclude research chemists from the class of people for whom an invention may be useful. 0 5 Under this rationale, utility to a research chemist alone is not patentable utility. The dissenters contended that these decisions would result in an increase of undesirable secrecy because few inventors will apply for patents on intermediates. 0 6 Patentability, on the other hand, would increase availability of these processes and compounds and would permit the research chemist to devote more time to research rather than first having to invent the chemical products necessary for investigation. Without such basic tools of research, progress declines-to the frustration of the constitutional design for the patent system. Contrary to this position and in support of the interpretation of the utility requirement which the majorities in Kirk, Joly, and Manson imposed is the argument that parallel lines of scientific development often occur independently. Failure to grant patent protection to one discoverer will not prevent others who simultaneously make the same discovery from working with the product or process.' 0 Granting a patent monopoly is therefore unnecessary to promote progress where progress is possible without the stimulation which patent protection provides. But even though such parallel discovery is possible, it frequently does not occur. And even when parallel discovery does occur, the vast majority of research scientists and inventors nevertheless have no opportunity to work with the product or process because they are not participants in the parallel discovery. 0 9 Hence, the possibility of parallel discovery is not a suitable basis for denying patents to research chemical compounds and processes.
B. Suggestion for a Standard of Utility
An early Supreme Court case established the following standard of utility: The determination of the presence or absence of utility must be made in the light of the common knowledge of persons skilled in the art." 0 The Supreme Court in Brenner v. Manson did not refer to this standard of utility. The dissenters in Kirk and Joly advocated readopting this standard by indicating that its application would involve an inquiry into what the chemists themselves consider useful in their work."' According to this standard, if a compound or process is useful to a research chemist in his research and the disclosure in the application is sufficient to show the chemist how to use the invention, then it fulfills the requirements of utility in section 101 and the requirements of disclosure in section 112.112
Such a standard is reasonable if one believes that the researcher makes his contribution to society at the time he discovers the compound or process and that the utility rests in the availability of the compound for further research."' The development of such intermediates as were present in Kirk and Joly is often the product of exhaustive research, and it is irrefutable that such research-when considered in its entirety-advances science and the useful arts and that "utility is characteristic of every phase of the project."" 4 Adopting this standard of utility would promote the progress of science and the public would benefit accordingly. More inventors would apply for patents on processes and compounds useful in research. Information about the discoveries would become available to the scientific community at an early stage. Consequently, more research into the uses of the new compounds and processes would result and the rate of discovery of uses would increase. Useful products and processes would become available to the public at a faster rate." 5 Furthermore, uniformity and ease of administration of the utility requirement would 
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Vglvel, supra n0ot 34, at 12; Note, 35 GEQ. WASr. L. Rsv. 809, 817 (1967) .
[Vol. 56:497 increase. The inventor and the patent office could more readily comprehend the requirements of utility and disclosure which each must respectively fulfill and administer. 1 6 In addition, the proposed standard of utility would more readily comport with that applied to tools which other scientists use. A new slide rule which is useful to those mathematicians trained in its use and a new surgeon's tool useful to a highly specialized surgeon possess patentable utility even though the general public cannot use these instruments. The benefit to the public results exclusively from the expert's use of the invention. Similarly, any benefit which the general public receives from the discovery of the steroid compounds in Kirk and Joly results from the use of these compounds by experts. In each case, the public does not benefit by being able to use the invention but receives a benefit through the expert's use of the invention.
It is arguable, however, that the general public receives a benefit from the expert's use of the slide rule or the surgical tool in a way that it does not benefit from the expert's use of the steroid compounds. The benefit to the public seems much more direct in the case of the slide rule or the surgeon's tool in that, whereas it is certain that the use of these instruments will lead to useful results in some instances, there is no similar assurance that the particular steroid will prove to possess some therapeutic value, and the patent should issue only after some particular steroid has shown some particular therapeutic value. The courts' greater willingness to allow patents to issue for mechanical inventions probably stems from the fact that it is often easier to visualize the benefit which society receives from such inventions than it is to visualize the benefit which the public receives from a chemical compound or process. There is no question, however, that the public does benefit from the progress in research which results from the discovery of these compounds and processes.
117 A reasonable interpretation of the utility requirement cannot distinguish among these three inventions on the basis of the benefit which the general public receives from each. The better rule would require deternuination of the presence or absence of utility in the light of the common knowledge of one who is skilled in the art. If the research chemist can show that the invention is useful to him in his research, then the invention should satisfy the requirement that it possess utility. 118 116 For a discussion of the difficulties involved in the administration of the rules as they now stand see In re Kirk, 376 F.2d 936, 957 (C.C.PA. 1967) (dissenting opinion).
117 See note 104 supra and accompanying text.
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For a discussion of possible constitutional objections to the adoption of such a rule and reasons why such objections do not constitute a serious bar to congressional action see Velvel, suPra note 34, at 13-14.
